Extracellular Vesicles and Circulating Nucleic Acids,
Год журнала:
2024,
Номер
5(4), С. 697 - 713
Опубликована: Ноя. 9, 2024
Aim:
The
article
explores
celery-derived
extracellular
vesicles
(CDEVs),
characterized
by
high
cellular
uptake,
low
immunogenicity,
and
stability,
as
a
therapeutic
strategy
for
antitumor
nanomedicines.
Methods:
methods
employed
in
this
study
include
vitro
cell
experiments
such
co-culture,
Western
Blot,
flow
cytometry.
In
vivo
were
conducted
C57BL/6
tumor-bearing
mice
subcutaneously
injected
with
Lewis
lung
carcinoma
(LLC)
cells.
encompassed
parameters
survival
rate,
body
weight,
tumor
size,
cytometry,
immunohistochemistry,
spectral
live
imaging
system.
Results:
Our
revealed
that
CDEVs
could
be
used
drugs
to
effectively
downregulate
the
phosphorylated
signal
transducer
activator
of
transcription
3
(p-STAT3)/programmed
death
ligand
1
(PD-L1)
axis
cancer
co-culture
experiments,
observed
impede
expression
PD-L1,
thereby
interfering
interaction
between
PD-L1
programmed
(PD-1)
subsequently
preventing
suppression
T
distribution
loaded
paclitaxel
(PTX)
demonstrated
better
targeting
capabilities.
Remarkably,
following
CDEVs-PTX
treatment,
CD8+
levels
increased,
presumably
leading
improved
effects.
Conclusion:
not
only
serve
drug
carriers
but
also
function
themselves;
such,
through
single
administration
CDEVs,
it
is
possible
combine
immunotherapy
chemotherapy
achieve
effects
two,
providing
more
comprehensive
effective
treatment
promises
improve
outcomes
reduce
adverse
therapy.
bioRxiv (Cold Spring Harbor Laboratory),
Год журнала:
2023,
Номер
unknown
Опубликована: Сен. 15, 2023
Abstract
Clinical
translation
of
gene
therapy
has
been
challenging,
due
to
limitations
in
current
delivery
vehicles
such
as
traditional
viral
vectors.
Herein,
we
report
the
use
gRNA:Cas9
ribonucleoprotein
(RNP)
complexes
engineered
extracellular
vesicles
(EVs)
for
vivo
therapy.
By
leveraging
a
novel
high-throughput
microfluidic
droplet-based
electroporation
system
(μDES),
achieved
10-fold
enhancement
loading
efficiency
and
more
than
1000-fold
increase
processing
throughput
on
RNP
into
EVs
(RNP-EVs),
compared
with
conventional
bulk
electroporation.
The
flow-through
droplets
serve
enormous
bioreactors
offering
millisecond
pulsed,
low-voltage
continuous-flow
scalable
manner,
which
minimizes
Joule
heating
influence
surface
alteration
retain
natural
EV
stability
integrity.
In
Shaker-1
mouse
model
dominant
progressive
hearing
loss,
demonstrated
effective
RNP-EVs
inner
ear
hair
cells,
clear
reduction
Myo7a
sh1
mRNA
expression
RNP-loaded
lipid-like
nanoparticles
(RNP-LNPs),
leading
significant
recovery
measured
by
auditory
brainstem
responses
(ABR).
One
sentence
summary
enables
vesicles,
leads
clinical
potential
employed
disease
Advanced Therapeutics,
Год журнала:
2024,
Номер
7(11)
Опубликована: Авг. 24, 2024
Abstract
Extracellular
vesicles
(EVs)
are
membranous
structures
secreted
by
cells
that
play
important
roles
in
intercellular
communication
and
material
transport.
Due
to
its
excellent
biocompatibility,
lipophilicity,
homing
properties,
EVs
have
been
used
as
a
new
generation
of
drug
delivery
systems
for
the
diagnosis
treatment
tumors.
Despite
potential
clinical
benefits
animal‐derived
extracellular
(AEVs),
their
large‐scale
production
remains
sluggish
due
exorbitant
cost
cell
culture,
challenging
quality
control
measures,
limited
capabilities.
This
constraint
significantly
hinders
widespread
application.
Plant‐derived
(PEVs)
share
similar
functionalities
with
AEVs,
yet
they
hold
several
advantages
including
wide
variety
source
materials,
cost‐effectiveness,
ease
preparation,
enhanced
safety,
more
stable
physicochemical
notable
efficacy.
These
merits
position
PEVs
promising
contenders
broad
biomedical
sector.
review
will
elucidate
PEVs,
delineating
therapeutic
mechanisms
cancer
treatment,
explore
prospective
applications
engineered
targeted
nano‐system
drugs,
microRNAs,
small
interfering
RNAs,
beyond.
The
aim
is
heighten
researchers’
focus
on
expedite
progression
from
fundamental
research
transformation
groundbreaking
discoveries.
Extracellular Vesicles and Circulating Nucleic Acids,
Год журнала:
2024,
Номер
5(4), С. 697 - 713
Опубликована: Ноя. 9, 2024
Aim:
The
article
explores
celery-derived
extracellular
vesicles
(CDEVs),
characterized
by
high
cellular
uptake,
low
immunogenicity,
and
stability,
as
a
therapeutic
strategy
for
antitumor
nanomedicines.
Methods:
methods
employed
in
this
study
include
vitro
cell
experiments
such
co-culture,
Western
Blot,
flow
cytometry.
In
vivo
were
conducted
C57BL/6
tumor-bearing
mice
subcutaneously
injected
with
Lewis
lung
carcinoma
(LLC)
cells.
encompassed
parameters
survival
rate,
body
weight,
tumor
size,
cytometry,
immunohistochemistry,
spectral
live
imaging
system.
Results:
Our
revealed
that
CDEVs
could
be
used
drugs
to
effectively
downregulate
the
phosphorylated
signal
transducer
activator
of
transcription
3
(p-STAT3)/programmed
death
ligand
1
(PD-L1)
axis
cancer
co-culture
experiments,
observed
impede
expression
PD-L1,
thereby
interfering
interaction
between
PD-L1
programmed
(PD-1)
subsequently
preventing
suppression
T
distribution
loaded
paclitaxel
(PTX)
demonstrated
better
targeting
capabilities.
Remarkably,
following
CDEVs-PTX
treatment,
CD8+
levels
increased,
presumably
leading
improved
effects.
Conclusion:
not
only
serve
drug
carriers
but
also
function
themselves;
such,
through
single
administration
CDEVs,
it
is
possible
combine
immunotherapy
chemotherapy
achieve
effects
two,
providing
more
comprehensive
effective
treatment
promises
improve
outcomes
reduce
adverse
therapy.
